AUPH - Aurinia Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.31
-0.01 (-0.16%)
At close: 4:00PM EDT

6.31 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close6.32
Open6.32
Bid6.30 x 3200
Ask6.37 x 1100
Day's Range6.22 - 6.38
52 Week Range5.06 - 7.85
Volume438,625
Avg. Volume894,177
Market Cap580.813M
Beta (3Y Monthly)0.15
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Big Pharma faces the Senate in drug price hearings
    Yahoo Finance Video2 months ago

    Big Pharma faces the Senate in drug price hearings

    Yahoo Finance's Adam Shapiro, Julie Hyman, Jessica Smith, and Brian Sozzi discuss the Pharma executives testifying in the Senate drug price hearings.

  • Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
    Zacks8 days ago

    Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

    Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

  • Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript

    AUPH earnings call for the period ending December 31, 2018.

  • Associated Presslast month

    Aurinia: 4Q Earnings Snapshot

    The Victoria, British Columbia-based company said it had a loss of 17 cents per share. The biotechnology company posted revenue of $29,000 in the period, missing Street forecasts. Three analysts surveyed ...

  • Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
    Zackslast month

    Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for

    Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • After Patent News, Aurinia Pharmaceuticals Still Has More to Prove
    InvestorPlace2 months ago

    After Patent News, Aurinia Pharmaceuticals Still Has More to Prove

    Aurinia Pharmaceuticals (NASDAQ:AUPH) leapt close to 20% on Monday. AUPH stock took off after the announcement of a new patent for the application method of its lupus nephritis drug.Source: Shutterstock This gave AUPH stock some much-needed excitement. Shares have languished between $5 and $6.50 for most of the past year, as investors await key clinical trial readouts. Bulls hope this patent news may finally break the gridlock and allow the stock to reach its highest levels in several years. However, Aurinia still has more work to do. Why The Patent News MattersThere was an interesting reaction with Aurinia stock after the news came out. At first, the stock didn't jump too much -- opening up just a few percent. But throughout the day, shares traded steadily higher as investors further considered the consequences.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 5 Clinical-Stage Biotech Stocks to Buy On the one hand, this is an important development for Aurinia. One of the lingering issues with Aurinia has been that the primary patents around its Voclosporin were initially set to expire in 2022.Normally, a biotech company has a much longer window to generate exclusive revenues from its products before generic competitors launch their own versions. Given that short window, bears have suggested that Aurinia would have issues profiting adequately when the drug comes to market.Aurinia had several options to deal with this issue. They already managed to use one regulatory pathway to get a five-year extension out of 2027. So that had reduced the investment risk substantially. Still, most clinical stage biotech companies have patent exclusivity much longer than eight years, so investors were right to price that in as a risk for AUPH stock.With this patent, Aurinia may have overcome this challenge. What Changed, And What Hasn'tOn Monday, Aurinia published a press release, stating:"Notably, the allowed claims cover a method of modifying the dose of voclosporin in patients with lupus nephritis (LN) based on patient specific pharmacodynamic parameters."The new patent on Voclosporin runs out through 2037, giving Aurinia excellent protection from generic competition.That said, reading carefully, we see that the patent covers modification of the dose of Voclosporin, not the actual drug itself. It's seemingly unclear if generics could still compete with Voclosporin as long as they use a different dosing method. And there's still another much bigger question to deal with first: Will the drug be approved? After all, a patent won't matter if the drug never makes it to market.The all-important Phase III trial is set to deliver results around the end of 2019. It's far from a given that Voclosporin will succeed and go on to obtain FDA approval. The company's previous trial ran into significant safety issues with patients dying during the study. Given the FDA's concerns on safety issues, investors should be careful about assuming approval before the definitive trial results come in.On top of that, in the previous trial, the company's lower dose version of the drug showed a stronger clinical effect than the higher dose version. Again, there is a plausible explanation for this: management suggests the higher dose version wasn't tolerated well in patients. Still, an inconsistent dose response is another caution flag for biotech trials.To summarize, while the patent news is a plus for AUPH stock, don't overlook the small matter that the drug still has to perform in its pivotal phase III trial and pick up FDA approval. AUPH Stock VerdictThe company does have a few other options beyond the key lupus trial. It is also testing Voclosporin for other conditions, such as dry eye. That program produced a mixed set of clinical results recently. It missed its key endpoint, but showed stronger efficacy than expected.It's unclear what exactly this will mean for the dry eye program going forward. In any case, phase III results are still a few years away. Additionally, there is much more competition in that market than there would be for lupus nephritis.So, despite the flurry of attention for dry eye that Aurinia proponents have shown, don't get distracted from the main event. The lupus results should be coming up within a year from now. Those results will determine whether or not AUPH stock delivers for its shareholders.Finally, I should note the unambiguously positive thing about Aurinia at this point: its strong fiscal position. As of the most recent quarter, it had $139 million in cash, and was burning ~$45 million annually. That gives it more than two years to keep advancing the clinical pipeline. * 7 IPOs to Get Excited for in 2019 On top of that, the company subsequently announced a $30 million stock offering, which will add a few more quarters worth of working cash to its already substantial treasury. While Aurinia's ultimate success is far from certain, they've got a respected management team and enough cash to give Voclosporin time to attempt to prove its potential.At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Consumer Stocks to Buy and Hold for Years * 4 China Stocks Soaring on Trade Hopes * 3 Esports Stocks to Benefit From the Boom Compare Brokers The post After Patent News, Aurinia Pharmaceuticals Still Has More to Prove appeared first on InvestorPlace.

  • Here's Why Aurinia Pharmaceuticals' Stock Jumped Today
    Motley Fool2 months ago

    Here's Why Aurinia Pharmaceuticals' Stock Jumped Today

    It looks like an important patent that could protect its lead candidate is a done deal.

  • Is Aurinia Pharmaceuticals a Buy?
    Motley Fool3 months ago

    Is Aurinia Pharmaceuticals a Buy?

    The pharma company bounced around for much of 2018, but there's intriguing potential in the pipeline.

  • Benzinga3 months ago

    Aurinia's Dry Eye Syndrome Drug Produces Mixed Results In Mid-Stage Trial

    Small-cap biotech Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) fell Tuesday morning following the release of clinical trial results. What Happened Aurinia said a mid-stage study that evaluated its dry eye ...

  • Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?
    Zacks3 months ago

    Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?

    Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

  • TheStreet.com3 months ago

    My Rx for How to Buy Aurinia Pharmaceuticals on Its Breakout

    In Tuesday's fast-paced Lightning Round of Jim Cramer's "Mad Money" program on CNBC, Jim commented that Aurinia Pharmaceuticals Inc. was "a great speculative stock." Let's check out the charts to see what sort of potential AUPH may have in the months ahead. In this daily bar chart of AUPH, below, we can see that prices broke out on the upside from a year-long sideways consolidation pattern.

  • Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
    Zacks5 months ago

    Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates

    Aurinia (AUPH) delivered earnings and revenue surprises of -23.53% and 476.92%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press5 months ago

    Aurinia: 3Q Earnings Snapshot

    The Victoria, British Columbia-based company said it had a loss of 21 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Here's What Pushed Aurinia Pharmaceuticals Inc. Up 16.8% in September
    Motley Fool6 months ago

    Here's What Pushed Aurinia Pharmaceuticals Inc. Up 16.8% in September

    Steady progress for the company's experimental lupus treatment took an important step forward

  • Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher
    Zacks7 months ago

    Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher

    Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Benzinga7 months ago

    The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 25) Abbott Laboratories (NYSE: ABT ) Amarin Corporation ...

  • Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates
    Zacks8 months ago

    Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

    Aurinia (AUPH) delivered earnings and revenue surprises of -18.75% and 447.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press8 months ago

    Aurinia: 2Q Earnings Snapshot

    The Victoria, British Columbia-based company said it had a loss of 19 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Aurinia Pharmaceuticals Inc’s (TSE:AUP) Shift From Loss To Profit
    Simply Wall St.8 months ago

    Aurinia Pharmaceuticals Inc’s (TSE:AUP) Shift From Loss To Profit

    Aurinia Pharmaceuticals Inc’s (TSE:AUP): Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada,Read More...

  • Investopedia9 months ago

    5 Favorite Biotech Bets

    Given their dependence on the success or failure of their drug candidates, biotechnology stocks are generally high-risk propositions. Over the past couple of decades our most profitable sector has been biotech stocks. Of course, the key to almost any stock move is news.

  • Here's Why Aurinia Pharmaceuticals Inc. Gained 32.2% in the First Half of 2018
    Motley Fool9 months ago

    Here's Why Aurinia Pharmaceuticals Inc. Gained 32.2% in the First Half of 2018

    An additional indication for the company's lead candidate has been a big source of encouragement.

  • InvestorPlace9 months ago

    Aurinia Pharmaceuticals Has Lots of Upside Potential

    Since last year, Aurinia Pharmaceuticals (NASDAQ:AUPH) has moved very little on the stock market. News of the launch of a mid-stage study, along with a quarterly earnings report before that, failed to ignite or hurt AUPH stock by much. On July 11, Aurinia launched a mid-stage Phase 2 clinical study that evaluates its drug, Voclosporin, for treating dry eye syndrome (or DES).

  • Benzinga9 months ago

    Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...

  • Breakeven On The Horizon For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
    Simply Wall St.10 months ago

    Breakeven On The Horizon For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

    Aurinia Pharmaceuticals Inc’s (NASDAQ:AUPH): Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada,Read More...

  • Here's Why Aurinia Pharmaceuticals Inc. Jumped 11% in May
    Motley Fool10 months ago

    Here's Why Aurinia Pharmaceuticals Inc. Jumped 11% in May

    Investors are excited about the potential for its lead drug to expand into additional diseases.